Table 1:
ALL N=222 |
Uncomplicated Cohort * N=103 |
Infants with either BPD, PH, and/or PDA N = 119 |
P-Value | |
---|---|---|---|---|
Birthweight (g) | 895 [767,1010] | 960 [805,1130] | 880 [750,980] | 0.007 |
Birthweight strata (g) | ||||
500 – 749 (n=43) | 650 [595,698] | 690 [650,700] | 640 [578.685] | 0.13 |
750 – 999 (n=90) | 880 [820,950] | 853 [809,940] | 890 [830,950] | 0.47 |
1000 – 1250 (n=89) | 1125 [903,1255] | 1140 [1052,1265] | 1110 [1045,1217] | 0.71 |
Gestational age | 27 [26,28] | 27 [26,28] | 26 [25,27] | <0.01 |
Gender (female) | 108 (49%) | 60 (58%) | 72 (60%) | 0.22 |
Race | 0.64 | |||
White | 156 (70%) | 91 (82%) | 68 (57%) | |
Black | 63 (54%) | 21 (20%) | 39 (33%) | |
Asian | 2 (2%) | 1 (1%) | 1 (1%) | |
Other | 1 (1%) | 0 | 1 (1%) | |
Ethnicity | 0.36 | |||
Hispanic or Latino | 3 (3%) | 2 (2%) | 1 (1%) | |
Not Hispanic or Latino | 219 (97%) | 101 (98%) | 118 (99%) | |
Maternal Smoking | 28 | 11 (11%) | 17 (14%) | 0.67 |
Antenatal corticosteroids | 197 (89%) | 99 (96%) | 98 (82%) | 0.76 |
Surfactant Replacement Therapy | 222 (100%) | 103 (100%) | 119 (100%) | 0.84 |
Multiples | 14 (6%) | 3 (3%) | 11 (9%) | 0.23 |
Cesarean section | 160 (72%) | 75 (73%) | 85 (71%) | 0.56 |
Maternal complications | ||||
Gestational DM | 10 (5%) | 7 (7%) | 3 (3%) | 0.57 |
Gestational HTN | 35 (16%) | 17 (17%) | 18 (15%) | 0.28 |
Prolonged rupture of membranes | 38 (17%) | 15 (15%) | 23 (19%) | 0.58 |
Chorioamnionitis | 20 (9%) | 10 (10%) | 10 (8%) | 0.51 |
Preeclampsia | 56 (25%) | 26 (26%) | 30 (25%) | 0.62 |
Placental Abruption | 38 (17%) | 17 (17%) | 21 (18%) | 0.89 |
Necrotizing enterocolitis | 21 (9%) | 11 (11%) | 10 (8%) | 0.53 |
ROP threshold (Stage 2 or higher) | 43 (19%) | 8 (9%) | 35 (29%) | 0.004 |
IVH (Grade 3 or 4) | 28 (13%) | 9 (9%) | 19 (16%) | 0.09 |
Total oxygen days (NICU) | 84 [40,107] | 34 [19,50] | 92 [82,115] | < 0.001 |
Length of stay (NICU) | 91 [76,114] | 79 [64,89] | 98 [87,119] | < 0.001 |
Data are presented as median [interquartile range], or number (Percentage)
BPD, bronchopulmonary dysplasia; PH, pulmonary hypertension; PDA, patent ductus arteriosus; DM, diabetes mellitus;
HTN, hypertension; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage
Healthy uncomplicated cohort, defined as preterm infants without BPD, echocardiographic signs of pulmonary hypertension at 32 or 36 weeks PMA, and/or a hemodynamically significant ductus arteriosus at day 5–7 or any size PDA at 32 or 36 weeks PMA.